Category: Gynecological

Simbionix wins grant to develop hysterectomy simulator

June 30, 2010 by MedCity News

By Brandon Glenn

The Israeli subsidiary of Simbionix USA and a Florida medical school have received a grant of an unspecified amount to develop a laparoscopic hysterectomy surgery simulator.

The grant comes from the U.S.-Israel Binational Industrial Research and Development Foundation, which promotes technology collaborations between companies and organizations from the two countries.

CerviLenz taps its first CFO/COO

June 28, 2010 by MedCity News

By Mary Vanac

Medical device start-up CerviLenz Inc. appointed its first CFO/COO: Federica “Freddi” O’Brien, a certified public accountant who spent the last decade working with bioscience companies.

J&J's Mentor Corp. settles ObTape liability lawsuits

June 9, 2010 by MassDevice staff

Johnson & Johnson (NYSE:JNJ) subsidiary Mentor Corp. agreed to settle a group of lawsuits filed against it over an allegedly defective device designed to treat female urinary incontinence.

CerviLenz plus progesterone could halve preterm birth risk

June 1, 2010 by MedCity News

By Mary Vanac

CerviLenz is a simple, low-tech medical device that prompts a “why didn’t I think of that?” response from many obstetricians.

Yet the device that quickly, accurately and inexpensively measures a pregnant woman’s cervix could help answer the $26 billion-a-year problem of preterm birth in the United States.

CerviLenz aims to lower preterm birth rate

May 21, 2010 by MedCity News

By Mary Vanac

A disposable device made by Chagrin Falls, Ohio-based CerviLenz Inc. aims to take the guesswork out of determining the risk of premature birth.

BioSphere parts ways with two executives

March 22, 2010 by MassDevice staff

Just two years after they came to the company, Williard Hennemann and Joel Weinstein will be departing Biosphere Medical Inc. (NSDQ:BSMD) for undisclosed reasons.

The company issued a sparsely worded release, saying only that the two would "cease to be employed by the company effective March 31, 2010."

INVO Bioscience touts South American infertility treatment trial results

February 5, 2010 by MassDevice staff

INVO Bioscience (OTC:IVOB) is touting the results of a South American clinical trial it says showed its INVOcell, a small capsule used to incubate eggs and sperm as an alternative to conventional infertility treatments, posted a 36 percent success rate in impregnating infertile women.

The Beverly, Mass.-based company said more than two-thirds of the 50 patients enrolled at the Center of Fertility and Sterility in Bogota, Colombia, reached the study's endpoint of clinical pregnancy, defined as a fetal heartbeat at seven weeks. That success rate puts the technique on par with other infertility treatments, company officials said, but with a much lower multiple pregnancy rate of 6 percent.